Biopharma/Biotech Companies Hiring Right Now in Philadelphia – Q1 2023

Updated January 2023

BioBuzz is committed to helping those impacted by recent layoffs. If you’ve been recently laid off, check out this resource and add your name to our growing list of professionals open to work.

With the dawn of a new year, companies across Cellicon Valley are bolstering their ranks as they look to the future.

BioBuzz rounds up some of the top Philadelphia life sciences companies looking to strengthen their teams for the coming year. The companies offer multiple job listings in different departments for candidates with a wide range of skills and experience levels.

Century Therapeutics

Headquartered in Philadelphia, Century Therapeutics is harnessing the capabilities of adult stem cells to develop best-in-class allogeneic iNK and iT cell therapies for different forms of cancer. The company leverages cellular reprogramming and genetic engineering to develop therapies that have the potential to overcome many of the challenges currently facing cell therapy.

Century Therapeutics is developing off-the-shelf cell therapies, including its lead asset, CNTY-101, an iPSC-derived chimeric antigen receptor iPSC-derived NK (CAR-iNK) cell therapy candidate being developed for the treatment of relapsed/refractory B-cell lymphoma. The company is currently recruiting patients for a Phase I trial.

In addition to CNTY-101, Century’s developmental pipeline includes CNTY-102, an iPSC-derived CAR gamma delta iT cell therapy candidate in development for relapsed/refractory B-cell lymphoma and other B-cell malignancies. CNTY-107 is an experimental gamma delta iT product candidate for the treatment of solid tumors expressing Nectin-4.

The company reduced its headcount at the beginning of the year in order to reprioritize its portfolio and extend its cash runway through 2026. Despite the cuts, Century Therapeutics is still advertising multiple roles to support its new strategic focus. Available positions can be found on the company’s web portal.

SwanBio Therapeutics

With a focus on developing gene therapies for neurodegenerative diseases, SwanBio Therapeutics closed out 2022 with the initiation of a first-in-human study of an AAV gene therapy for Adrenomyeloneuropathy, a progressive disease caused by mutations in the ABCD1 gene. The mutations lead to disruptions in the function of spinal cord cells and other tissues. The disease affects approximately 10,000 people in the U.S. and Europe.

SwanBio is developing SBT101, a gene therapy that has received both Fast Track and Orphan Drug designation from the FDA. The Phase I/II trial that began at the end of the year will assess the safety and efficacy of SBT101.

The company’s gene therapy research is fueled by a $56 million Series B financing round closed in May 2022.

The Philadelphia-based company currently has multiple job openings in quality assurance, project management and more. Interested employees can access the company’s jobs portal on its website.

Integral Molecular

A leader in antibody discovery for membrane proteins, Integral Molecular is hiring for multiple positions in research and administration at its Philadelphia-based headquarters. Applications can be found at the company’s online jobs portal.

Integral Molecular has become an integral partner for multiple companies. With more than two decades of experience focused on researching membrane proteins and antibodies, the company’s assets have been incorporated into the drug discovery pipelines of hundreds of biotech and pharmaceutical companies. Integral Molecular’s research is playing a unique role in the development of new therapies for cancer, autoimmune disorders and diabetes. The company’s research is also lending vital support into treatments for viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses.

Integral Molecular kicked off 2023 by publishing the targeting mechanism specificity for its Claudin 6 (CLDN6) antibody CTIM-76 being developed for Context Therapeutics. In its publication, Integral Molecular researchers show the isolation of highly specific CLDN6 antibodies. This research is key due to similarities in targets expressed with Claudins 3, 4 and 9, the company noted in its announcement. A non-specific binding could kill healthy tissues in off-target areas, the company said.


A global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, IQVIA has numerous available positions in the City of Brotherly Love. Listings on the company’s online career page show positions that include project leader roles, as well as clinical research roles in oncology.

IQVIA’s headquarters are in North Carolina’s Research Triangle Park, but its reach spans the globe. The company’s work is powered by its IQVIA Connected Intelligence platform that speeds up the clinical development process in order to accelerate the availability of innovative medical treatments.


Oncology-focused Imvax is building a team to support development of personalized cancer medications aimed at halting tumor development through the stimulation of the immune system. The company’s lead asset is IGV-001, an experimental treatment for glioblastoma.

IGV-001 combines personalized, autologous whole-tumor derived cells with an antisense oligonucleotide. Phase Ib data presented in 2021 showed significant potential in the treatment of glioblastoma. The company is preparing a Phase II study with the asset.

As Imvax rolls into 2023, the Philadelphia-based company is poised to hire for numerous positions, including roles in R&D, regulatory affairs, quality assurance and more. Available positions can be found at the company’s website.

For a wider window into what companies are hiring in the Philadelphia area, or across the BioHealth Capital Region, visit the BioBuzz Job Board search engine, a free resource for job seekers looking to enter the biotech industry or take that next step in their life sciences careers.